Canada · Delayed Price · Currency is CAD Theralase Technologies Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw a 45% revenue increase and a 30% reduction in net loss, driven by device sales and cost controls. Clinical milestones include completed enrollment in the phase II bladder cancer study and plans for a new drug application in Q3 2026, with regulatory decisions expected in H1 2027.
Fiscal Year 2025
-
Completed phase II bladder cancer study enrollment, reported strong interim efficacy and safety, and maintained disciplined financial management amid declining device revenues. Preparing for regulatory submissions in 2026 and expanding pipeline into multiple oncology and virology indications.
-
Enrollment in the pivotal bladder cancer study is nearing completion, with strong interim efficacy and safety data supporting a planned regulatory submission in late 2026. Financial discipline continues, with new capital raised and strategic initiatives underway to expand the pipeline and pursue a U.S. listing.
Fiscal Year 2024
-
Revenue declined 3% year-over-year, with net loss narrowing due to lower R&D spending. Strong clinical results in the Phase II bladder cancer study support ongoing regulatory and funding efforts, while the company pursues additional financing and strategic partnerships.
-
Revenue declined 12% year-over-year, with a 7% reduction in net loss due to lower R&D spending. Strong interim clinical results in bladder cancer support ongoing FDA engagement and commercialization plans, with significant capital raised and further funding initiatives underway.